Roche drops India patent for breast-cancer drug (Update)

August 17, 2013 by Penelope Macrae

Swiss pharmaceutical giant Roche says it is abandoning a patent for top-selling breast cancer drug Herceptin in the Indian market, paving the way for local drugmakers to make a cheaper generic version.

The decision comes after an Indian health ministry committee earlier this year urged the government to issue a "compulsory licence" that would have obliged Roche to license a domestic generic firm to make a much cheaper copy.

"Roche has come to the conclusion not to pursue" the patent, the company said in an emailed statement to AFP late Friday.

Roche said its decision to relinquish its patent took "into account the strength of the particular rights and the IP (intellectual property) environment in India in general".

India's patent laws are tougher than in many other countries as part of attempts to make medicines more affordable to its vast poor population.

This has led to a string of patent setbacks in India for Western drugmakers which have been engaged in a series of intellectual property battles.

Indian patient rights groups accuse Western pharmaceutical firms of greedy pricing that denies impoverished patients in India and across the world access to vital medicines.

India, known as the "pharmacy to the world", has a huge generic drug industry that turns out cheaper copycat versions of life-saving branded medicines.

The active ingredient of Herceptin, used to treat an extremely aggressive form of breast cancer, was discovered before 1995 when India did not recognise patents.

To join the World Trade Organization, India had to change its law but it did not start recognising drug patents until 2005. Even then, it gave patent protection only to drugs discovered after 1995.

Roche obtained an Indian patent for Herceptin six years ago that involved a different composition of the drug.

But that patent was challenged by India's Cancer Patients' Aid Association as insufficiently innovative.

Indian law refuses patents for tweaks to drugs—so-called "evergreening".

"They (Roche) had seen the writing on the wall, they knew the Herceptin patent had been granted on very shaky legal grounds," Kalyani Menon Sen, a leading campaigner for affordable medicines, told AFP.

Earlier this year, India said in a ruling on Novartis's leukaemia drug Glivec that no new patent for a reformulations of an old medicine could be granted unless they displayed a "significant therapeutic improvement".

Like Roche's Herceptin, Glivec's main ingredient was discovered before 1995.

Roche did not disclose its price for Trastuzumab, sold under the brand name Herceptin, but said it had a "local pricing policy".

Patient rights groups said the drug cost 92,000 rupees ($1,490) for a single dose, and called the price "exorbitant" in a country like India.

"More than a million women (in India) have been diagnosed (with aggressive HE2+ breast cancer) in the six years that this patent has been in force—with less than 10 percent able to access the drug," Sen said.

Roche said Herceptin would remain on sale in India. It has global patents on Herceptin running through 2019.

It noted there were "no approved bio-similars (copies) of Herceptin in India" yet but Sen said two Indian firms are working on generic equivalents.

Explore further: India revokes cancer drug patent in fresh industry blow

Related Stories

India revokes cancer drug patent in fresh industry blow

August 2, 2013
India has revoked a local patent granted to Britain's GlaxoSmithKline for a breast cancer drug in the latest blow to global companies seeking a bigger presence in the country's $13 billion medicine market.

India generics giant wins cancer drug patent case

September 8, 2012
Indian generics giant Cipla says it has scored a "landmark" court win in a patent challenge launched by Switzerland's Roche Holding over the Mumbai firm's version of a lung-cancer drug.

Drug maker Novartis loses India patent battle (Update)

April 1, 2013
India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world will get continued ...

Bayer vows to fight for patent on anti-cancer drug in India

March 4, 2013
German pharmaceuticals giant Bayer, maker of Aspirin, vowed Monday to fight a ruling by the patent authorities in India allowing a local company to produce and sell a generic copy of its anti-cancer drug Nexavar.

India's top court to deliver Novartis judgment

March 31, 2013
India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG that focuses on demands by major companies that their investments be protected, against Indian companies that say they ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.